Anebulo Pharmaceuticals annual r&d spending
2021
2022
2023
2024
2025
Anebulo Pharmaceuticals R&D Spending Growth & History (ANEB)
Anebulo Pharmaceuticals's r&d spending was $4.3M for fiscal 2025.
View full Anebulo Pharmaceuticals company overviewAnebulo Pharmaceuticals annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-06-30 | $4.3M | $751,004 | +21.16% |
| 2024 | 2024-06-30 | $3.5M | −$2.1M | −36.63% |
| 2023 | 2023-06-30 | $5.6M | $2.6M | +89.10% |
| 2022 | 2022-06-30 | $3.0M | $691,540 | +30.46% |
| 2021 | 2021-06-30 | $2.3M | — | — |
Anebulo Pharmaceuticals quarterly r&d spending
Q2.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2025-12-31 | $1.2M | −$55,798 | −4.57% |
| Q1 2026 | 2025-09-30 | $809,991 | −$504,868 | −38.40% |
| Q4 2025 | 2025-06-30 | $1.1M | $658,517 | +140.80% |
| Q3 2025 | 2025-03-31 | $638,324 | −$110,015 | −14.70% |
| Q2 2025 | 2024-12-31 | $1.2M | $157,863 | +14.86% |
| Q1 2025 | 2024-09-30 | $1.3M | $44,639 | +3.51% |
| Q4 2024 | 2024-06-30 | $467,706 | −$949,453 | −67.00% |
| Q3 2024 | 2024-03-31 | $748,339 | −$341,003 | −31.30% |
| Q2 2024 | 2023-12-31 | $1.1M | −$807,248 | −43.17% |
| Q1 2024 | 2023-09-30 | $1.3M | $46,444 | +3.80% |
| Q4 2023 | 2023-06-30 | $1.4M | $299,018 | +26.74% |
| Q3 2023 | 2023-03-31 | $1.1M | $173,979 | +19.01% |
| Q2 2023 | 2022-12-31 | $1.9M | $1.7M | +778.16% |
| Q1 2023 | 2022-09-30 | $1.2M | $508,678 | +71.13% |
| Q4 2022 | 2022-06-30 | $1.1M | −$688,551 | −38.11% |
| Q3 2022 | 2022-03-31 | $915,363 | $642,325 | +235.25% |
| Q2 2022 | 2021-12-31 | $212,936 | $42,954 | +25.27% |
| Q1 2022 | 2021-09-30 | $715,098 | $694,812 | +3425.08% |
| Q4 2021 | 2021-06-30 | $1.8M | $1.7M | +1104.46% |
| Q3 2021 | 2021-03-31 | $273,038 | — | — |
| Q2 2021 | 2020-12-31 | $169,982 | — | — |
| Q1 2021 | 2020-09-30 | $20,286 | — | — |
| Q2 2020 | 2020-06-30 | $150,000 | — | — |
Anebulo Pharmaceuticals r&d spending trends
Between the periods ended 2021-06-30 and 2025-06-30, Anebulo Pharmaceuticals's r&d spending increased from $2.3M to $4.3M, a change of $2.0M. The latest reported quarter, Q2 2026, shows $1.2M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Anebulo Pharmaceuticals source filings ↗